Longevity AI and Clalit Health Group are retraining cardiovascular and Type 2 diabetes risk prediction models using real-world longitudinal data from nearly five million patients across integrated healthcare systems. Improved risk stratification at earlier stages enables more targeted preventive intervention before disease progression.
Key Points
- Real-world data recalibration improves prediction accuracy for CVD and T2D
- Earlier risk identification enables personalized preventive care strategies
- Integration with electronic medical records surfaces actionable patient risks
Longevity Analysis
The ability to identify cardiovascular and metabolic disease risk before symptomatic onset is foundational to extending healthspan. Standard risk models rely on population averages and cross-sectional snapshots; longitudinal recalibration against integrated clinical data—laboratory values, imaging, medication histories, treatment outcomes across institutional settings—reveals individual deviation patterns that precede clinical events. This approach acknowledges that disease emerges from the interaction of multiple physiological systems over time, not from single biomarkers. Earlier detection coupled with personalized prevention addresses the interval between risk identification and intervention, where most lifestyle and therapeutic modifications can still alter trajectory.
Original published by LT Wire.